Hemophilia Drugs Market 2019 Analysis, Exhibit 6.0% CAGR and Remarkable Growth Rate forecast till 2025

Hemophilia Drugs Market is projected for better diagnosis because patients with hemophilia suffer from an abnormal blood loss and this weakens their blood clotting process, Hemophilia Drugs Industry exhibit a 6.0% & strong growth in the coming years

pune, india - May 16, 2019 /MarketersMedia/ —

The Global Hemophilia Drugs Market covered a value of US$ 9875.4 Mn in the year 2017 and is anticipated to reach US$ 15830.3 Mn by 2025. Furthermore, the global market for hemodialysis is expected to report a CAGR of 6.0% during the forecast period. The above information was published in a report, titled “Hemophilia Drugs Market Size, Share and Global Trend by Disease Indication (Hemophilia A, B & C), Therapy Type (Recombinant Therapy, Plasma therapy & Others), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2025.”

The rising prevalence of severe diseases is one of the major concerns in the healthcare industry. Among these disorders, patients with hemophilia suffer from an abnormal blood loss and this weakens their blood clotting process. Companies are introducing novel hemophilia drugs and therapies to fulfil the unmet needs of patients and maintain their quality of life. A lead analyst at Fortune Business Insights said, “Companies are building expansion strategies to develop new hemophilia drugs so as to offer better diagnosis.”

Among disease indications, hemophilia A is projected to exhibit a strong growth in the coming years. In addition to this, this segment covered a share of 85% in the global hemophilia drugs market in 2017. This is mainly attributable to the rising pool patients suffering from hemophilia across the world. Also, rising initiatives at developing and commercializing new products for the effective treatment of hemophilia is driving this segment’s growth. Following hemophilia A, hemophilia B drugs are also expected to grow at a considerable rate in the years to come.

Request Sample Copy at https://www.fortunebusinessinsights.com/enquiry/sample/hemophilia-drugs-market-100068

Asia Pacific to Grow at a Rapid Pace with Rising Number of Hemophilia Patients

North America is projected to emerge dominant in the global hemophilia drugs market during the forecast period. This is mainly ascribable to the rising prevalence of hemophilia A and B, especially in countries such as Canada and the U.S. Moreover, in 2017, North America market for hemophilia drugs covered a value of US$ 3,684.7 Mn. Trailing North America, Europe is the second-leading region in the global hemophilia drugs market. The growth in this region is attributable to the rising healthcare budgets by governments and initiatives by governments to promote hemophilia drugs treatment. On the other hand, the hemophilia drugs market in Asia Pacific is likely to expand at a higher CAGR between 2017 and 2025 on account of rising number of patients suffering from hemophilia especially in countries such as China and India.

Rising Awareness About Hemophilia to Augment the Demand

The primary factor augmenting the hemophilia drugs market is the recent developments in hemophilia treatment. A lead analyst at Fortune Business Insights said “Several new drugs are expected to enter the global market in the coming years.” Also, hemophilia surgical management is gaining traction on account of increasing awareness about hemophilia across the world. Moreover, governments are planning to conduct awareness initiatives to spread knowledge regarding the use of hemophilia treatment and drugs This, in turn, is expected to drive the hemophilia drugs market over the next few years. The genetic evolution is leading to rising incidences of bleeding disorders across the world. This will further lead to hemophilia drug development in the next few years to come. As per the study conducted by the National Hemophilia Foundation or NHF in 2015, about 1% of the U.S. population is likely to suffer from a disease called von Willebrand, hence rising the need for hemophilia treatment drugs.

Pfizer Introduced Gene Therapy to Address Unmet Patient’s Needs

Some of the leading players presently operating in the global market for hemophilia drugs are Grifols SA, Bioverativ Inc., FERRING LÄKEMEDEL AB, Aptevo Therapeutics, Hoffmann-La Roche Ltd, Novo Nordisk, Pfizer, Inc. and CSL Behring. In 2018, companies such as Novo Nordisk, Takeda Pharmaceutical Company Ltd., and F. Hoffmann-La Roche Ltd covered more than half of the share in the global hemodialysis market as per revenue. In 2017, Pfizer, Inc. collaborated with Sangamo Therapeutics, Inc. to commercialize and develop gene therapy programs. The aim was to utilize these programs for Hemophilia A drugs.

Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/hemophilia-drugs-market-100068

About us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Info:
Name: Fortune Business Insights
Email: Send Email
Organization: Fortune Business Insights
Address: Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India
Phone: 1 424 253 0390
Website: https://www.fortunebusinessinsights.com

Source URL: https://marketersmedia.com/hemophilia-drugs-market-2019-analysis-exhibit-60-cagr-and-remarkable-growth-rate-forecast-till-2025/513243

Source: MarketersMedia

Release ID: 513243

Latest News

Prince Harry accepts apology for intrusive images

May 20, 2019

LONDON — Prince Harry settled privacy and data protection claims Thursday against a news agency that hovered over his home in a helicopter and took photos directly into his living room and bedroom. Harry accepted substantial damages and an apology from Splash News and Picture Agency. The figure was not disclosed. In a statement read at High Court in London on Harry's behalf, his attorney Gerrard Tyrrell said the rural retreat in Oxfordshire, southern England was chosen because of "the high level of privacy it afforded," but that now he and his wife Meghan feel "they are no longer able...

UK has first week without burning coal for electricity

May 20, 2019

LONDON — Britain has gone a week without burning coal for electricity for the first time since the 19th century. Power operator National Grid says coal hasn't contributed to the U.K. electricity mix since the afternoon of May 1. The landmark was reached two years after Britain had its first coal-free day since the Industrial Revolution. Fintan Slye, director of National Grid Electricity System Operator, said Wednesday that coal-free power would become the "new normal" as Britain generates more power from wind, solar and other renewable sources. The U.K. also relies heavily on natural gas and nuclear energy. The government...

UN panel calls WikiLeaks founder's UK sentence excessive

May 20, 2019

LONDON — A panel of legal experts affiliated with the United Nations has criticized the 50-week sentence a British judge imposed on WikiLeaks founder Julian Assange for jumping bail. The Working Group on Arbitrary Detention said Friday that Assange's punishment was "disproportionate" for his "minor violation." The panel questioned why he is being held in a high security prison "as if he were convicted for a serious criminal offense." A judge in London sentenced the 47-year-old Assange on Wednesday for taking refuge in the Ecuadorian Embassy while he was on bail awaiting extradition to Sweden The U.N. panel declared in...

UK climate panel sets big goals: less meat, electric cars

May 20, 2019

LONDON — The U.K. should eliminate almost all greenhouse gas emissions by 2050 by rapidly adopting policies that will change everything from the way people heat their homes to what they eat, an independent committee that advises the British government on climate change recommended Thursday. A report from the Committee on Climate Change said the government must adopt ambitious goals if it wants to be a leader in the fight against global warming and limit the impact of climate change. While Britain has laid the groundwork to achieve net-zero emissions of greenhouse gases, existing plans "must be urgently strengthened" because...

UK's fired defense secretary furiously denies Huawei leak

May 20, 2019

LONDON — Britain's former defense secretary ferociously denied allegations that he leaked details from private government discussions about the Chinese telecommunications company Huawei, as opposition leaders called Thursday for a criminal investigation into the scandal. Gavin Williamson was fired from the government's top defense job late Wednesday by Prime Minister Theresa May, who said she had seen "compelling evidence" that he was behind media reports that the government had agreed — against the advice of the United States — to let Huawei participate in some aspects of Britain's new 5G wireless communications network. It was the first time in decades...

Sign up now!

About Us

Future Science Today reports on captivating developments in science, medicine, technology, and the world around us.

Contact us: sales[at]futuresciencetoday.com